Corvia Medical Reports Results of Corvia Atrial Shunt in P-III (REDUCE LAP-HF II) Trial for the Treatment of Heart Failure
Shots:
- The P-III (REDUCE LAP-HF II) trial evaluating Corvia Atrial Shunt in 626 patients with HFpEF or HFmrEF at 89 centers across the US, Canada, EU, Australia & Japan
- The results showed a 45% reduction in HF events and a ≥55% improvement in health status as measured by KCCQ with 40% more shunt patients reporting a very large improvement (≥20 points) in QoL compared to sham control in a large responder population represented 50% of study patients treated with the Corvia Atrial Shunt
- Additionally, the results showed that patients without a pacemaker and with normal exercise PVR showed a 50% of the total study population demonstrated a significant clinical benefit
Ref: PR Newswire | Image: Corvia
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
